Cellular Biomedicine Group Inc Revenue Growth Rates (CBMG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cellular Biomedicine Group Inc   (NASDAQ: CBMG)
 

CBMG's Revenue Growth by Quarter and Year

Cellular Biomedicine Group Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CBMG Revenue (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
4th Quarter December -
3rd Quarter September 0.03
2nd Quarter June 0.12
1st Quarter March 1.23
FY 1.38

CBMGs Annual Revenue
Cellular Biomedicine Group Inc 's Revenue in the fiscal year 2019 $ 0.34 millions
Cellular Biomedicine Group Inc 's Revenue in the fiscal year 2018 $ 0.22 millions
Cellular Biomedicine Group Inc 's Revenue in the fiscal year 2017 $ 0.34 millions
Cellular Biomedicine Group Inc 's Revenue in the fiscal year 2016 $ 0.63 millions
Cellular Biomedicine Group Inc 's Revenue in the fiscal year 2015 $ 2.51 millions




CBMG Revenue third quarter 2020 Y/Y Growth Comment
Cellular Biomedicine Group Inc reported drop in Revenue in the third quarter 2020 by -87.58% to $ 0.03 millions, from the same quarter in 2019.
The fall in the third quarter 2020 Cellular Biomedicine Group Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 3072.62%.

Looking into third quarter 2020 results within Biotechnology & Pharmaceuticals industry 70 other companies have achieved higher Revenue growth. While Cellular Biomedicine Group Inc ' s Revenue meltdown of -87.58% ranks overall at the positon no. 4234 in the third quarter 2020.


CBMG Revenue ( Y/Y Growth %) 2020
 2019 2018 2017
4th Quarter December - 866.67 % -57.14 % 16.67 %
3rd Quarter September -87.58 % 271.43 % -36.36 % 1000 %
2nd Quarter June -90.48 % 1475 % 33.33 % -14.29 %
1st Quarter March 2360 % 0 % -50 % -79.59 %
FY   - 708.7 % -32.35 % -

Financial Statements
Cellular Biomedicine Group Inc 's third quarter 2020 Revenue $ 0.03 millions CBMG's Income Statement
Cellular Biomedicine Group Inc 's third quarter 2019 Revenue $ 0.26 millions Quarterly CBMG's Income Statement


CBMG Revenue (Quarter on Quarter Growth %)

 2020
 2019 2018 2017
4th Quarter December - 11.54 % -57.14 % -36.36 %
3rd Quarter September -73.09 % -79.37 % -12.5 % 83.33 %
2nd Quarter June -90.24 % 2420 % 60 % -40 %
1st Quarter March 324.14 % 66.67 % -28.57 % 66.67 %
FY (Year on Year)   - 708.7 % -32.35 % -


Back to CBMG Growth rate Comparisons >> Back to CBMG Growth rate Comparisons >>


Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #71
Healthcare Sector #639
Overall #4234

Revenue Y/Y Growth Statistics
High Average Low
79608.75 % 3072.62 % -100 %
 
Revenue third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #71
Healthcare Sector #639
Overall #4234
Revenue Y/Y Growth Statistics
High Average Low
79608.75 % 3072.62 % -100 %
 

Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Cellular Biomedicine Group Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
229824.63 % 7638.53 % -100 %
(Dec 31 2012)  


CBMG's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2020 Cellular Biomedicine Group Inc disclosed fall in Revenue from the second quarter by -73.09% to $ 0.03 millions, from $ 0.12 millions achived in the previous reporting period.

But that's not important problem, as Cellular Biomedicine Group Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 78 other companies have achieved higher Revenue quarter on quarter growth. While Cellular Biomedicine Group Inc 's Revenue growth quarter on quarter, overall rank is 4536.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #79
Healthcare Sector #718
Overall #4536
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #79
Healthcare Sector #718
Overall #4536
Revenue Q/Q Growth Statistics
High Average Low
229824.63 % 7638.53 % -100 %
(Dec 31 2012)  


CBMG's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2020 Cellular Biomedicine Group Inc disclosed fall in Revenue from the second quarter by -73.09% to $ 0.03 millions, from $ 0.12 millions achived in the previous reporting period.

But that's not important problem, as Cellular Biomedicine Group Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 78 other companies have achieved higher Revenue quarter on quarter growth. While Cellular Biomedicine Group Inc 's Revenue growth quarter on quarter, overall rank is 4536.


Cellular Biomedicine Group Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)		 12 Months Ending
(Dec 31 2019)		 12 Months Ending
(Sep 30 2019)
Cumulative Revenue 12 Months Ending $ 1.68 $ 1.91 $ 3.04 $ 1.86 $ 1.60
Y / Y Revenue Growth (TTM) 4.83 % 35.37 % 1266.2 % 730.46 % 497.85 %
Year on Year Revenue Growth Overall Ranking # 1493 # 505 # 21 # 55 # 52
Seqeuential Revenue Change (TTM) -12.04 % -37.38 % 63.27 % 16.57 % 13.59 %
Seq. Revenue Growth (TTM) Overall Ranking # 1493 # 505 # 21 # 55 # 52


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2020 period, Cellular Biomedicine Group Inc 's cumulative twelve months Revenue were $ 2 millions, company would post below average annual Revenue growth of 13.59% year on year, if the fiscal year would end at Sep 30 2020.
A slow-down in the Cellular Biomedicine Group Inc 's Revenue growth from the 1.4073839999999997% growth in Jun 30 2020.

Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 505 to 1493.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 23
Overall # 50

Revenue TTM Y/Y Growth Statistics
High Average Low
1266.2 %
 128.04 %
-177.25 %
(Mar 31 2020)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 221
S&P 500 # 944
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2020 period, Cellular Biomedicine Group Inc 's cumulative twelve months Revenue were $ 2 millions, company would post below average annual Revenue growth of -177.25% year on year, if the fiscal year would end at Sep 30 2020.
A slow-down in the Cellular Biomedicine Group Inc 's Revenue growth from the 1.4073839999999997% growth in Jun 30 2020.

Within the Healthcare sector 22 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 505 to 1493.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 23
Overall # 50

Revenue TTM Y/Y Growth Statistics
High Average Low
1266.2 %
128.04 %
-177.25 %
(Mar 31 2020)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 26
Sector # 221
S&P 500 # 944




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CBMG's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2020
Ensign Group Inc-0.21%$ -0.208 millions
Crh Medical Corporation-0.21%$ -0.215 millions
Radnet Inc -0.24%$ -0.237 millions
Tenet Healthcare Corp-0.24%$ -0.241 millions
Prestige Consumer Healthcare Inc -0.27%$ -0.272 millions
Establishment Labs Holdings Inc -0.42%$ -0.420 millions
Cocrystal Pharma Inc -0.61%$ -0.610 millions
American Renal Associates Holdings Inc -0.82%$ -0.823 millions
Rockwell Medical inc -0.83%$ -0.826 millions
Tactile Systems Technology Inc -1.05%$ -1.048 millions
Icon Plc-1.23%$ -1.226 millions
American Bio Medica Corporation-1.34%$ -1.341 millions
Transmedics Group Inc -1.58%$ -1.582 millions
Boston Scientific Corporation-1.77%$ -1.773 millions
Bruker Corporation-1.86%$ -1.861 millions
Orthofix Medical Inc -2.21%$ -2.215 millions
Encision Inc -2.29%$ -2.288 millions
Integra Lifesciences Holdings Corp-2.34%$ -2.338 millions
Neurometrix Inc -2.48%$ -2.480 millions
Lifevantage Corp-2.49%$ -2.492 millions
Macrogenics Inc -2.60%$ -2.604 millions
Surgalign Holdings Inc -2.70%$ -2.704 millions
Alimera Sciences Inc-2.93%$ -2.934 millions
Fortress Biotech Inc -3.04%$ -3.039 millions
Teleflex Incorporated-3.09%$ -3.088 millions
Adm Tronics Unlimited Inc -3.10%$ -3.105 millions
Bausch Health Companies Inc -3.21%$ -3.214 millions
Atricure Inc -3.28%$ -3.280 millions
Aspira Women s Health inc -3.58%$ -3.580 millions
Electromed Inc -3.59%$ -3.593 millions


About Cellular Biomedicine Group Inc Revenue Growth Rates (CBMG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.